November 21, 2025 16:30 ET | Source: Olema Oncology SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”,…
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase…
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/…
November 14, 2025 17:30 ET | Source: Avicanna Inc. TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or…
EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative…
Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease modelsSafety data from Phase 1 on…
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol…
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II…
October 29, 2025 20:00 ET | Source: ASCENTAGE PHARMA GROUP INTERNATIONAL ROCKVILLE, Md. and SUZHOU, China, Oct. 29, 2025 (GLOBE…